Growth Metrics

Q32 Bio (QTTB) Debt Ratio (2023 - 2026)

Q32 Bio's quarterly Debt Ratio came in at 0.13 in Q1 2026, down 20.04% year-on-year from 0.16 in Q1 2025, and down 18.27% quarter-over-quarter from 0.16 in Q4 2025.

Q32 Bio has reported Debt Ratio for 4 years, with the latest figure at 0.13 in Q1 2026.

  • For the quarter ending Q1 2026, Debt Ratio fell 20.04% year-over-year to 0.13; the trailing twelve-month figure through Mar 2026 stood at 0.13 (down 20.04% YoY), and the FY2025 full-year result was 0.16, up 14.67% from the prior year.
  • Debt Ratio for Q1 2026 stood at 0.13, down from 0.16 in the prior quarter.
  • The five-year high for Debt Ratio was 0.19 in Q3 2025, with the low at 0.08 in Q1 2024.
  • Average Debt Ratio over 4 years is 0.14, with a median of 0.13 recorded in 2024.
  • Year-over-year, Debt Ratio jumped 95.94% in 2025 and slipped 20.04% in 2026.
  • Tracing QTTB's Debt Ratio over 4 years: stood at 0.12 in 2023, then increased by 18.13% to 0.14 in 2024, then climbed by 14.67% to 0.16 in 2025, then decreased by 18.27% to 0.13 in 2026.
  • The last three Debt Ratio figures came in at 0.13 (Q1 2026), 0.16 (Q4 2025), and 0.19 (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Debt Ratio (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn 0.18
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - 1.41
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn -
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 0.05
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn -
10 Q32 Bio 162.94 Mn 112.19 Mn - 0.13

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 0.13
Dec 31, 2025 0.16
Sep 30, 2025 0.19
Jun 30, 2025 0.19
Mar 31, 2025 0.16
Dec 31, 2024 0.14
Sep 30, 2024 0.12
Jun 30, 2024 0.10
Mar 31, 2024 0.08
Dec 31, 2023 0.12